Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-Label, Single Ascending Dose Study to Assess the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee

Next Previous
Trial Profile

An Open-Label, Single Ascending Dose Study to Assess the Safety and Tolerability of FX201 in Patients with Osteoarthritis of the Knee

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 21 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Enekinragene inzadenovec (Primary)
  • Indications Musculoskeletal pain; Osteoarthritis
  • Focus Adverse reactions; First in man
  • Sponsors Flexion Therapeutics; Pacira BioSciences

Most Recent Events

  • 15 May 2025 According to a Pacira BioSciences media release, The research findings are being presented during a podium session at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting in New Orleans on May 15, 2025, at 2:15 CT.
  • 06 May 2025 According to a Pacira BioSciences media release, company will present result data from this study at the 2025 European Alliance of Associations for Rheumatology (EULAR) Annual Congress, taking place from June 11-14, in Barcelona, Spain.
  • 28 Apr 2025 According to a Pacira BioSciences media release,the results data from this trial was presented during a poster session at the 2025 Osteoarthritis Research Society International (OARSI) World Congress in Incheon, South Korea, on Friday, April 25, and Saturday, April 26.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top